EMERYVILLE, Calif., June 13,
2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL),
the functional cell biology company, today announced that the
Company's technology was recently featured in a groundbreaking
study published in Cell Reports titled "Potent
Omicron-neutralizing antibodies isolated from a patient vaccinated
six months before Omicron emergence" that has revealed the
remarkable efficacy of vaccines in generating potent antibodies
against emerging variants at an accelerated rate.
The study, conducted by researchers from the La Jolla
Institute for Immunology, highlights the pivotal role of scientific
collaboration and speed in combating the global health crisis.
PhenomeX's Beacon platform played a crucial role in identifying
antibodies from a previously vaccinated patient that exhibited
broad activity against multiple Omicron lineages. These monoclonal
antibodies (mAbs) also demonstrated exceptional protective efficacy
in a mouse model of BA.1 and BA.2 infection.
The findings of this study provide compelling evidence that
vaccination can elicit antibodies that effectively combat emerging
variants such as Omicron. Furthermore, the identification of mAbs
exhibiting therapeutic efficacy against BA.1 and BA.2 in a mouse
model suggests their potential as a viable treatment option for
COVID-19.
PhenomeX's Beacon platform and antibody discovery protocol
enabled the isolation of individual B cells, allowing for the
screening of secreted antibodies for reactivity to Delta-Spike
antigens. The Beacon platform facilitated the rapid identification
of potent omicron-neutralizing antibodies six months prior to the
emergence of the Omicron variant, showcasing the potential for
accelerated vaccine development and therapeutic interventions.
"Infectious diseases like SARS-CoV-2 can rapidly develop
dangerous variants, necessitating the need for tools that can
swiftly identify effective antibodies against emerging strains,"
said Dr. Siddhartha Kadia, chief executive officer of PhenomeX.
"The Beacon platform, with its proven speed and accuracy, played a
pivotal role in identifying potent omicron-neutralizing antibodies
that are enabling researchers to gain crucial insights into
potential treatment options."
This study underscores the importance of ongoing efforts to
develop durable therapeutics and highlights the indispensable role
of scientific collaboration in addressing the challenges posed by
the global health crisis.
To read additional PhenomeX use cases for single-cell functional
biology, visit the publications page on our website.
About PhenomeX Inc.
PhenomeX is empowering scientists to leverage the full potential
of each cell and drive the next era of functional
cell biology that will advance human health. We enable
scientists to reveal the most complete insights on cell function
and obtain a full view of the behavior of each cell. Our unique
suite of proven high-throughput tools and services offer
unparalleled resolution and speed, accelerating the insights that
are key to advancing discoveries that can profoundly improve the
prevention and treatment of disease. Our award-winning
platforms are used by researchers across the globe, including those
at the top 15 global pharmaceutical companies and approximately 85%
of leading U.S. comprehensive cancer centers.
Forward-Looking Statements
To the extent that
statements contained in this press release are not descriptions of
historical facts regarding PhenomeX or its products, they are
forward-looking statements reflecting the current beliefs and
expectations of management. Such forward-looking statements involve
substantial known and unknown risks and uncertainties that relate
to future events, and actual results and product performance could
differ significantly from those expressed or implied by the
forward-looking statements. PhenomeX undertakes no obligation to
update or revise any forward-looking statements. For a further
description of the risks and uncertainties relating to the
Company's growth and continual evolution see the statements in the
"Risk Factors" sections, and elsewhere, in our filings with the
U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phenomexs-beacon-technology-enables-early-identification-of-potent-omicron-neutralizing-antibodies-301849579.html
SOURCE PhenomeX